Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: August 4, 2004
Last updated: January 15, 2013
Last verified: January 2013

RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining different types of biological therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and sargramostim together with monoclonal antibody 3F8 works in treating patients with neuroblastoma that has not responded to previous treatment.

Condition Intervention Phase
Biological: beta-glucan
Biological: monoclonal antibody 3F8
Biological: sargramostim
Drug: isotretinoin
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Disease response as assessed by PT-PC at the end of 4 courses

Estimated Enrollment: 74
Study Start Date: July 2004
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the efficacy of beta-glucan, isotretinoin, and sargramostim (GM-CSF) in enhancing monoclonal antibody 3F8-mediated ablation in patients with high-risk refractory neuroblastoma.
  • Determine the antitumor activity of this regimen, in terms of assessing disease status in the bone marrow by real-time quantitative reverse transcription polymerase chain reaction, in these patients.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: This is an open-label study. Patients are stratified according to refractory disease (primary refractory [never had disease progression or disease recurrence] vs secondary refractory [recurrent disease that did not respond completely to reinduction therapy]).

  • Courses 1 and 2: Patients receive sargramostim (GM-CSF) subcutaneously once daily on days -5 to 11. Patients also receive oral beta-glucan once daily on days -2 to 11 and monoclonal antibody (MOAB) 3F8 IV over 30-90 minutes on days 0-4 and 7-11.
  • Courses 3 and 4: Patients receive GM-CSF, beta-glucan, and MOAB 3F8 as above. Patients also receive oral isotretinoin twice daily on days -2 to 11.

Treatment repeats every 2-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 27-74 patients (10-33 for stratum 1 and 17-41 for stratum 2) will be accrued for this study.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of neuroblastoma, as defined by 1 of the following:

    • Histologically confirmed disease
    • Bone marrow metastases plus high urine catecholamines
  • High-risk disease meeting 1 of the following stage criteria:

    • Stage IV, with 1 of the following:

      • Any age with MYCN amplification
      • > 18 months of age without MYCN amplification
    • Stage III, with both of the following:

      • Any age with MYCN amplification
      • Unresectable disease
    • Stage 4S with MYCN amplification
  • Measurable or evaluable soft tissue disease
  • Relapsed disease resistant to standard induction chemotherapy and salvage therapy



  • Any age

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • No severe hepatic toxicity ≥ grade 3


  • No severe renal toxicity ≥ grade 3


  • No severe cardiac toxicity ≥ grade 3


  • No severe pulmonary toxicity ≥ grade 3


  • Not pregnant
  • Negative pregnancy test
  • No severe neurologic toxicity ≥ grade 3
  • No severe gastrointestinal toxicity ≥ grade 3
  • No other severe major organ dysfunction except ototoxicity
  • No history of allergy to mouse proteins
  • No active life-threatening infection
  • No human anti-mouse antibody titer > 1,000 ELISA units/mL


Biologic therapy

  • Not specified


  • See Disease Characteristics

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00089258

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Nai-Kong V. Cheung, MD, PhD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00089258     History of Changes
Other Study ID Numbers: 04-050
Study First Received: August 4, 2004
Last Updated: January 15, 2013

Keywords provided by Memorial Sloan Kettering Cancer Center:
localized unresectable neuroblastoma
disseminated neuroblastoma
regional neuroblastoma
stage 4S neuroblastoma
recurrent neuroblastoma

Additional relevant MeSH terms:
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Dermatologic Agents processed this record on April 28, 2017